Drug-coated balloons (DCB) and drug-eluting stents (DES) have significantly altered
treatment paradigms for femoropopliteal lesions. We aimed to describe changes in practice
patterns as a result of the infusion of these technologies into the treatment of peripheral
arterial disease. We queried the Vascular Quality Initiative (VQI) registry from 2010–2017
for all peripheral vascular interventions (PVI) involving the superficial femoral
artery (SFA) and/or the popliteal artery. Cases were divided into a PRE and a POST
era with a cutoff of September 2016 when specific device identity was first recorded
in VQI. For each artery, a primary treatment was identified as either plain balloon
angioplasty (POBA), atherectomy, DCB, bare-metal stent (BMS), or DES. The relative
distribution of primary treatments between the PRE and POST eras was evaluated, as
were lesion characteristics associated with DCB and DES utilization and regional variability
in the adoption of these new technologies. Of 210,666 arteries in the dataset, 91,864
femoropopliteal arteries (across 74,842 procedures in 55,437 patients) were included.
Each artery received 1.5 ± 0.6 treatments. Primary treatment utilization changed from
40% balloon angioplasty, 45% stenting, and 15% atherectomy in the PRE era to 22% POBA,
26% BMS, 8% atherectomy, 37% DCB, and 8% DES in the POST era (P < .001). 43% of arteries
received a drug-containing device as a primary or adjunctive therapy and 1.3% received
both a DCB and DES in the POST era. DCB utilization as the primary treatment was highest
in lesions with length 10–19.9 cm (42%), TASC A-C lesions (38%), and lesions with
mild to no calcification (38%). DES utilization was highest in lesions with length
20+ cm (12%), TASC D lesions (13%), and lesions with moderate to severe calcification
(9%). The range of utilization across 18 regions was 12–40% for DCB and 1–14% for
DES. Regional variability was greater for DES (SD 4% vs. mean 8%) than for DCB (SD
7% vs. mean 29%). There has been a rapid dissemination of DCB and DES technology in
the femoropopliteal vessels, with nearly half of arteries receiving a drug-containing
therapy in modern practice. DCBs are most utilized in medium-length, minimally calcified
lesions, while DESs are most utilized in longer, more heavily calcified lesions. There
is significant regional variability in adoption, especially with DES. This Vascular
Quality Initiative (VQI) study of 91,864 femoropopliteal endovascular procedures found
that 43% were treated recently with drug coated balloons (DCB) or drug coated stents
(DES). DES use was less prevalent and more variable than DCB use.